Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CALCRL | Q16602 | 14/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.52 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.46 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.45 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.45 |
| ▸ | ACHE | P22303 | 1/20 | 0.44 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.43 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3593468 | 0.86 | CALCRL (0.48) | CALCRLCYP3A4DPP8OPRM1OPRK1 | |
| SCHEMBL4593330 | 0.86 | CALCRL (0.56) | CALCRLCYP3A4DPP8OPRM1OPRK1 | |
| SCHEMBL3601504 | 0.86 | CALCRL (0.56) | CALCRLCYP3A4DPP8OPRM1OPRK1 | |
| SCHEMBL3601983 | 0.81 | OPRD1 (0.61) | CALCRLCYP3A4DPP8CHRM1OPRD1 | |
| SCHEMBL3596301 | 0.81 | OPRD1 (0.61) | CALCRLCYP3A4DPP8CHRM1OPRD1 | |
| Hydrochloric Acid SCHEMBL3757142 | 0.80 | OPRD1 (0.60) | CALCRLCYP3A4DPP8OPRM1OPRK1 | |
| SCHEMBL3601861 | 0.79 | CALCRL (0.51) | CALCRLCYP3A4OPRM1OPRK1CHRM1 | |
| SCHEMBL4862832 | 0.79 | CALCRL (0.51) | CALCRLCYP3A4OPRM1OPRK1CHRM1 | |
| SCHEMBL13052620 | 0.78 | CALCRL (0.77) | CALCRLCYP3A4 | |
| SCHEMBL3604155 | 0.74 | CPA1 (0.53) | DPP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7842808-B2 | calcitonin gene-related peptide receptors antagonists such as 4-(2-Oxo-2,3-dihydro-benzoimidazol-1-yl)-piperidine-1-carboxylic acid[2-(1,4-dioxa-8-aza-spiro [4.5]dec-8-yl)-1-(1H-indol-5-ylmethyl)-2-oxo-ethyl]-amide, used for treating headaches, pain, hot flashes or respiratory system disorders | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-11-30 | — | — | US | disclosed |
| US-7754732-B2 | Spirocyclic anti-migraine compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-07-13 | — | — | US | disclosed |
| US-20070149503-A1 | ANTI-MIGRAINE SPIROCYCLES | BRISTOL-MYERS SQUIBB COMPANY | 2007-06-28 | — | — | US | disclosed |
| US-20070149502-A1 | SPIROCYCLIC ANTI-MIGRAINE COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY | 2007-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070149503-A1 | ANTI-MIGRAINE SPIROCYCLES | CALCRL, CALCR, CALCA | CALCRL 1/4885CYP3A4 3214/4885DPP8 3812/4885 |
| US-20070149502-A1 | SPIROCYCLIC ANTI-MIGRAINE COMPOUNDS | CALCRL, CALCR, CALCA | CALCRL 1/4885CYP3A4 3426/4885DPP8 4025/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.